Why is Biogen Pharma falling/rising?

As of 28-Aug, Biogen Pharmachem Industries Ltd is experiencing a decline in its stock price, currently at 0.89, which reflects a decrease of 0.01 or 1.11%. The stock has been trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 47.29% compared to the 5-day average. Over the past week, the stock has decreased by 3.26%, and it has shown a year-to-date decline of 24.58%. Despite declaring positive results for the last two consecutive quarters, including a remarkable growth in profit before tax and profit after tax, the company's weak long-term fundamental strength, characterized by a low return on equity and poor ability to service debt, raises concerns among investors.
In the broader market context, Biogen Pharma's recent performance has been underwhelming compared to the benchmark Sensex, which has only declined by 2.34% in the past week. The stock's year-over-year return of -37.76% starkly contrasts with the Sensex's slight decrease of 2.08%, highlighting its underperformance. The stock's valuation appears expensive relative to its peers, further contributing to the negative sentiment. Overall, while the company has reported positive quarterly results, the persistent issues regarding its financial health and investor confidence are driving the stock's downward movement.